Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics

Cardiovascular Drugs and Therapy

Volumn 12, Issue 5, 1998, Pages 475-482

  Kanki, Hideaki ^a   Mitamura, Hideo ^a   Takatsuki, Seiji ^a   Sueyoshi, Kouichiro ^a   Shinagawa, Kaori ^a   Sato, Toshiaki ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arrhythmia; Atrial fibrillation; Refractory period; Sodium channels

Indexed keywords

PILSICAINIDE; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATHETER; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION SYSTEM; HEART REPOLARIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; SINUS NODE CONDUCTION VELOCITY; VAGUS NERVE STIMULATION;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; KINETICS; LIDOCAINE; MALE; SODIUM CHANNEL BLOCKERS;

EID: 0032434686     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007758217189     Document Type: Article

References (33)

1. Herre JM, Scheinman MM. Supraventricular tachycardia. In: Parmley WW, Chatterjee K, Cheitlin MD, Karliner JS, Rapaport E, Scheinman MM, eds. Cardiology: Physiology, Pharmacology, Diagnosis. Philadelphia: J.B. Lippincott, 1988:1-19.
2. Kannel WE, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982; 308:1018-1022.
3. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959;58:59-70.
4. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn 1962;140:183-188.
5. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964;67:200-220.
6. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet hypothsis of atrial fibrillation. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton, 1985:265-274.
7. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravnous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;70:693-696.
8. Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol 1996;19:409-412.
9. Miyano S, Sumoto K, Satoh F, et al. New antiarrhythmic agents. N-aryl-8-pyrrolizidinealkanamides. J Med Chem 1985;28:714-717.
10. Hattori Y, Inomata N, Aisaka K, Ishihara T. Electrophysiological action of N-(2,6-dimethylphenyl) -8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986;8: 998-1002.
11. Inomata N, Ishihara T, Akaike T. SUN1165, a new antiarrhythmic Na current blocker in ventricular myocytes of guinea pig. Comp Biochem Physiol 1987;87C:237-243.
12. Wang Z, Page P, Nattel S. The mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992;71:271-287.
13. Atarashi H, Inoue H, Hiejima K, Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol 1996;78:694-697.
14. Kirchhof C, Wijffels M, Brugada J, Planellas J, Allessie M. Mode of action of a new class Ic drug (Org7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol 1991;17:116-124.
15. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action atrial fibrillation. The importance of use-dependent effects on refractoriness. Circulation 1993;88:1030-1044.
16. Whalley DW, Grant AO. Role of sodium and potassium channels in atrial electrogenesis and their blockade by antiarrhythmic drugs. In: DiMarco JP, Prystowsky EN, eds. Atrial Arrhythmias: State of the Arts. Armonk, NY: Futura Publishing, 1995:171-200.
17. Roden DM. Treatment of cardivascular disorders: Arrhythmias. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds. Clinical Pharmacology: Basic Principles in Therapeutics. New York: McGraw-Hill, 1992:151-185.
18. Rosen MR. Effect of pharmacological agents on mechanisms responsible for reentry. In: Kulbertus HE, ed. Reentrant Arrhythmias: Mechanisms and Treatment. Baltimore, MD: University Park Press, 1976:283-294.
19. Nakaya Y-Nii H, Nomura M, Fujino K, Mori H. Effects of lidocaine and quinidine on post-repolarization refractoriness after the basic and premature action potentials: Consideration of aim of antiarrhythmic drug therapy. Am Heart J 1989;118:907-912.
20. Nakaya Y, Elharrar V, Surawicz B. Effect of mexiletine, amiodarone and disopyramide on the excitability and refractoriness of canine cardiac fibers: Possible relation to antiarrhythmic drug action and classification. Cardiovasc Drugs Ther 1987;1:141-153.
21. Campbell TJ. Kinetics of onset of rate dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983; 17:344-352.
22. Inoue M, Inoue D, Ishibashi K, et al. Effect of pilsicainide on the atrial fibrillation threshold in guinea pig atria A comparative study with disopyramide, lidocaine and flecainide. Jpn Heart J 1993;34:301-312.
23. Hattori Y, Inomata N, Aisaka K, Ishihara T. Electrophysiological action of N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986;8: 998-1002.
24. Weirich J, Hohnloser S, Antoni H. Differential analysis of frequency-dependent effects of antiarrhythmic drugs: Importance of the saturation behavior of frequency-dependent sodium-channel blockade. J Cardiovasc Pharmacol 1992; 20(Suppl. 2):S8-S16.
25. Costard-Jaeckle A, Liem LB, Franz MR. Frequency-dependent effect of quinidine, mexiletine, and their combination on postrepolarization refractoriness in vivo. J Cardiovasc Pharmacol 1989;14:810-817.
26. Franz MR, Costard A. Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ. Circulation 1988;77:1177-1184.
27. Hondeghem LM, Katzung BG. Time- and voltage-dependent interaction of antiarrythmic drugs with sodium channels. Biochem Biophys Acta 1977;472:373-98.
28. Hille B. Local anesthestecs. Hydrophilic and Hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497-515.
29. Inomata N, Ohno T, Ishihara T, Akaike N. Antiarrhythmic agents act differently on the activation phase of the Ach-response in guinea-pig atrial myocytes. Br J Pharmacol 1993;108:111-115.
30. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
31. Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, Van der Lugt JT. Efficacy of ibutilide for termination of atrial figrillation and flutter. Am J Cardiol 1996; 78:42-45.
32. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996;78:46-52.
33. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997;29:385-390.